EX-FILING FEES 6 tm2212977d1_ex-filingfees.htm EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Tables

FORM S-3
(Form Type)

Protalix BioTherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

Security Type

Security Class Title

Fee Calculation or Carry Forward Rule

Amount Registered(1)

Proposed Maximum Offering Price Per Unit

Maximum Aggregate Offering Price

Fee Rate

Amount of Registration Fee

Carry Forward Form Type

Carry Forward File Number

Carry Forward Initial Effective Date

Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward

Newly Registered Securities

Fees to Be Paid

Equity

Common Stock

Rule 457(o)

Fees to Be Paid

Equity

Preferred Stock

Rule 457(o)

Fees to Be Paid

Debt

Debt Securities

Rule 457(o)

Fees to Be Paid

Equity

Warrants

Rule 457(o)

Unallocated (Universal) Shelf

$

100,000,000

0.0000927

$

9,270.00

Carry Forward Securities

Total Offering Amounts

$

100,000,000

$

9,270.00

Total Fees Previously Paid

—

Total Fee Offsets

$

5,557.01

Net Fee Due

$

3,712.99

(1) There are being registered under this registration statement such indeterminate number of shares of common stock and preferred stock, debt securities and/or warrants of the Registrant as shall have an aggregate initial offering price not to exceed $100,000,000. Any securities registered under this registration statement may be sold separately or as units with other securities registered under this registration statement. The proposed maximum initial offering prices per unit will be determined, from time to time, by the Registrant in connection with the issuance by the Registrant of the securities registered under this registration statement. The securities registered also include such indeterminate amounts and numbers of common stock as may be issued upon conversion of or exchange for preferred stock, debt securities or warrants that provide for such conversion or exchange.

Table 2: Fee Offset Claims and Sources

Registrant or Filer Name

Form or Filing Type

File Number

Initial Filing Date

Filing Date

Fee Offset Claimed

Security Type Associated with Fee Offset Claimed

Security Title Associated with Fee Offset Claimed

Unsold Securities Associated with Fee Offset Claimed

Unsold Aggregate Offering Amount Associated with Fee Offset Claimed

Fee Paid with Fee Offset Source

Rule 457(p)

Fee Offset Claims

Protalix BioTherapeutics, Inc.

S-3

333-230604

03/29/2019

$

5,557.01

Unallocated (Universal) Shelf

(1

)

(1

)

(1

)

(1) On March 29, 2019, the registrant initially filed a Registration Statement on Form S-3 (File No. 333-230604) (the “Original Registration Statement”), which registered (i) an aggregate principal amount of $100,000,000 of Common Stock, $0.001 par value per share, Preferred Stock, $0.001 par value per share, Debt Securities and Warrants to be offered by the registrant from time to time (together, the “Original Offerings”). This gross proceeds from the Original Offerings were $54,150,046.56. The Original Registration Statement expired on April 12, 2022. Pursuant to Rule 457(p) under the Securities Act, the Registrant is carrying forward to this registration statement $5,557.01 that was previously paid in connection with the Registrant’s prior registration statement (File No. 333-230604).